Copyright Nasdaq. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria
Clinical Proof-of-Concept Data for First GalXC™ RNAi Product Candidate Expected in Second Half of 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc . (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human in...
View HTML
Toggle Summary Dicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the inaugural...
View HTML
Toggle Summary Dicerna to Present at the Stifel 2017 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Stifel 2017...
View HTML
Toggle Summary Dicerna Reports Third Quarter 2017 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the third quarter...
View HTML
Toggle Summary Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH) Dicerna to receive up to $201 million in upfront and success-based development and commercialization milestones, excluding royalties, for an...
View HTML
Toggle Summary Dicerna to Report Third Quarter 2017 Financial Results and Host Conference Call on November 2, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2017 financial results after market close on Thursday, November...
View HTML
Toggle Summary Dicerna Files Clinical Trial Application for DCR-PHXC, the Company's Most Advanced GalXC™ Product Candidate, for Phase 1 Study in Primary Hyperoxaluria (PH)
The Company Expects to Initiate Clinical Dosing in Q1 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the first submission of a clinical trial application (CTA) to...
View HTML
Toggle Summary Dicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable Series
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in an analyst-led...
View HTML
Toggle Summary Dicerna to Present at Rodman & Renshaw 19th Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Rodman & Renshaw...
View HTML
Toggle Summary Dicerna Reports Second Quarter 2017 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the second quarter...
View HTML